FDA to evaluate Avastin for deadly form of brain cancer

03/10/2009 | Forbes

An FDA panel is scheduled March 31 to review Genentech's application to promote Avastin as a treatment for a deadly form of brain cancer called glioblastoma multiforme. Avastin, which is approved to treat colon, breast and lung cancers, generated $2.69 billion in U.S. sales last year.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY